During the past decade, Instituto Nacional de Enfermedades Respiratorias conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 14 clinical trials were completed, i.e. on average, 56% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional de Enfermedades Respiratorias" #1 sponsor was "Instituto Nacional de Enfermedades Respiratorias" with 6 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 5 trials sponsored and "National Institute of Respiratory Diseases, Mexico" with 5 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional de Enfermedades Respiratorias" #1 collaborator was "American College of Rheumatology" with 1 trials as a collaborator, "Cambridge University Hospitals NHS Foundation Trust" with 1 trials as a collaborator, "Cook Ireland, Ltd." with 1 trials as a collaborator, "Fundación Clínica Médica Sur" with 1 trials as a collaborator and "Hospital Infantil de Mexico Federico Gomez" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional de Enfermedades Respiratorias" are "COVID-19" (8 trials), "Idiopathic Pulmonary Fibrosis" (4 trials), "Aspirin-exacerbated Respiratory Disease" (2 trials), "COPD" (2 trials) and "Covid19" (2 trials). Many other conditions were trialed in "Instituto Nacional de Enfermedades Respiratorias" in a lesser frequency.

Most popular intervention types in "Instituto Nacional de Enfermedades Respiratorias" are "Drug" (22 trials), "Other" (9 trials), "Procedure" (3 trials), "Device" (2 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Remdesivir" (4 trials), "Nintedanib" (3 trials), "Baricitinib" (2 trials) and "Crizotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional de Enfermedades Respiratorias" are 36 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto Nacional de Enfermedades Respiratorias". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Instituto Nacional de Enfermedades Respiratorias, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional de Enfermedades Respiratorias, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".